Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07503808 · ClinicalTrials.gov registry record · Phase 1
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
A Phase 1 study, sponsored by IDEAYA Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT07503808 is a Phase 1 study that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 150 participants.
The verdict
NCT07503808, a Phase 1 study, is actively recruiting participants, sponsored by IDEAYA Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
Interventions
- DRUG IDE034
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07503808
The ClinicalTrials.gov registry entry for NCT07503808 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IDEAYA Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IDE034 is the first listed.
NCT07503808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07503808 about?
NCT07503808 is a clinical study titled "A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types". This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
What is the current status of trial NCT07503808?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2026-02-24. Estimated completion is 2027-07-30.
What interventions are being tested in trial NCT07503808?
The interventions under investigation include: IDE034 (DRUG).
Who is sponsoring clinical trial NCT07503808?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.